146 related articles for article (PubMed ID: 23952683)
1. Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.
Sun H; Li Y; Li D; Hou T
J Chem Inf Model; 2013 Sep; 53(9):2376-89. PubMed ID: 23952683
[TBL] [Abstract][Full Text] [Related]
2. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.
Sun HY; Ji FQ
Biochem Biophys Res Commun; 2012 Jun; 423(2):319-24. PubMed ID: 22659414
[TBL] [Abstract][Full Text] [Related]
3. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract][Full Text] [Related]
5. Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Huang Q; Johnson TW; Bailey S; Brooun A; Bunker KD; Burke BJ; Collins MR; Cook AS; Cui JJ; Dack KN; Deal JG; Deng YL; Dinh D; Engstrom LD; He M; Hoffman J; Hoffman RL; Johnson PS; Kania RS; Lam H; Lam JL; Le PT; Li Q; Lingardo L; Liu W; Lu MW; McTigue M; Palmer CL; Richardson PF; Sach NW; Shen H; Smeal T; Smith GL; Stewart AE; Timofeevski S; Tsaparikos K; Wang H; Zhu H; Zhu J; Zou HY; Edwards MP
J Med Chem; 2014 Feb; 57(4):1170-87. PubMed ID: 24432909
[TBL] [Abstract][Full Text] [Related]
6. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
[TBL] [Abstract][Full Text] [Related]
7. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
Ni Z; Zhang TC
J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
9. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
10. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
11. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
Roskoski R
Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
[TBL] [Abstract][Full Text] [Related]
12. L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.
Li J; Sun R; Wu Y; Song M; Li J; Yang Q; Chen X; Bao J; Zhao Q
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245558
[TBL] [Abstract][Full Text] [Related]
13. Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase.
Kumar A; Shanthi V; Ramanathan K
Mol Inform; 2015 Feb; 34(2-3):105-14. PubMed ID: 27490033
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
15. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
16. The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.
Alshareef A; Zhang HF; Huang YH; Wu C; Zhang JD; Wang P; El-Sehemy A; Fares M; Lai R
Sci Rep; 2016 Sep; 6():33710. PubMed ID: 27641368
[TBL] [Abstract][Full Text] [Related]
17. Analyzing resistance pattern of non-small cell lung cancer to crizotinib using molecular dynamic approaches.
Kumar A; Ramanathan K
Indian J Biochem Biophys; 2015 Feb; 52(1):23-8. PubMed ID: 26040108
[TBL] [Abstract][Full Text] [Related]
18. Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach.
Kumar A; Ramanathan K
J Mol Model; 2014 Jul; 20(7):2324. PubMed ID: 24952065
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7.
Takeoka K; Okumura A; Maesako Y; Akasaka T; Ohno H
Cancer Genet; 2015 Mar; 208(3):85-90. PubMed ID: 25766836
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]